Powerful 5.8-magnitude earthquake rocks Turkey, killing at least 1 as people jump from windows amid panic
The earthquake struck around 2:17 a.m. local time Tuesday morning (7:17 p.m. ET Monday) south of Marmaris, Turkey, with shaking reported across the region, including Rhodes, Greece.
Marmaris Gov. Dr. Idris Akbiyik took to social media shortly after the earthquake and said that while there were no immediate reports of significant damage, several people were injured and at least one person was killed.
Akbiyik said a 14-year-old girl was brought to a local hospital after suffering from a 'panic attack,' and despite life-saving measures, she was pronounced dead.
In addition, Akbiyik said several people were injured after jumping from windows to escape homes and other structures to get outdoors for safety.
3 A magnitude 5.8 earthquake rattled coastal communities in southwestern Turkey early Tuesday morning.
X / @LastQuake
3 The earthquake struck around 2:17 a.m. local time Tuesday morning (7:17 p.m. ET Monday) south of Marmaris, Turkey.
X / @idrisakbiyik
3 Several people were injured and at least one person was killed.
Storyful / @mr.softwareengineer
Information in this article was translated via Google Translate.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
12 hours ago
- Business Wire
Pulse Biosciences To Present at the 45 th Canaccord Genuity Annual Growth Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present at the upcoming 45 th Canaccord Genuity Annual Growth Conference in Boston. Pulse Biosciences' Management is scheduled to present on Wednesday, August 13, 2025, at 11:00 am ET. A live and recorded webcast of the presentation will be available on the 'Events Calendar and Presentations' page of the company's investor website at About Pulse Biosciences ® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company's proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA, nanosecond PFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
CNBC
13 hours ago
- CNBC
Trump's drug price ultimatum sets pharma firms scrambling
Pharmaceutical firms are scrambling to respond to a fresh ultimatum from U.S. President Donald Trump demanding "binding commitments" to lower their drug prices stateside . The White House said Thursday that President Trump had sent letters to 17 major pharmaceutical firms outlining the steps they must take to lower the price of U.S. prescription drugs to "most favored nation" (MFN) levels by Sept. 29. They were told that if they "refuse to step up," the government will deploy every tool in its "arsenal to protect American families from continued abusive drug pricing practices," without stating what those measures could be. The companies to receive letters were AbbVie , Amgen , AstraZeneca , Boehringer Ingelheim, Bristol-Myers Squibb , Eli Lilly , EMD Serono, Roche' s subsidiary Genentech, Gilead , GSK , Johnson & Johnson , Merck , Novartis , Novo Nordisk , Pfizer , Regeneron and Sanofi . Healthcare stocks tumbled Friday, following broader market losses as investors digested Trump's amended trade tariffs. Shares of Wegovy-maker Novo Nordisk dropped 5% in early morning trade before paring losses to trade 1.3% lower at 11:15 a.m. London time (6:15 a.m. ET). Companies were informed that they must provide MFN prices to all Medicaid patients, the U.S. health program for low-income patients. They were also told not to offer medicines to other developed markets at better prices than those offered in the U.S., and that they should sell drugs directly to U.S. patients, thereby cutting out pharmacy middlemen known as pharmacy benefit managers (PBMs). Trump has long lambasted pharmaceutical firms for what he dubs are unfair pricing practices, previously saying that he planned to bring down U.S. prices by 80%. In May, the president signed an executive order to lower drug costs by tying the prices of some medicines in the U.S. to the significantly lower ones abroad under the MFN policy. The U.S. consistently pays the most in the world for many prescription drugs, due in part to the U.S.′ highly complex and fragmented reimbursement system and lack of national pricing control. The latest announcement comes as the pharmaceutical industry is also calling for clarity on potential industry-wide tariffs. Trump previously warned these could run as high as 200%. Many companies have nevertheless shared that they agree with some of Trump's concerns. AstraZeneca CEO Pascal Soriot said Tuesday that the Anglo-Swedish firm had been liaising closely with the U.S. administration over the MFN policy and investment in U.S. manufacturing more broadly. Last week, it announced plans to invest $50 billion in the U.S., following a slew of other pharma firms. "There are issues around prices. I personally believe the president is right to say price equalization should happen," Soriot told reporters on an earnings call. Vas Narasimhan, CEO of Swiss-headquartered Novartis, also said last month that the firm was pursuing an MFN policy to lower U.S. drug prices. JPMorgan analysts said in a note Friday that while the latest announcement was intended to serve as a stark warning, ongoing talks between with the U.S. administration could buy pharma firms some time to respond. "While the government's latest announcement may appear harsh, we think it is likely that the matter is being discussed to some extent between the companies and the government, and we believe no changes that would have a significant negative impact on pharmaceutical companies will occur in the short term," analysts led by Seiji Wakao said in a note to clients.
Hamilton Spectator
2 days ago
- Hamilton Spectator
The News Forum to Exclusively Air Ground-breaking Documentary 'Fixing Canada's Health Care: Lessons from Japan'
ST. CATHARINES, Ontario, July 31, 2025 (GLOBE NEWSWIRE) — The News Forum, Canada's independent leading news network dedicated to balanced and diverse perspectives, is proud to announce the exclusive broadcast premiere of the new 22-minute documentary, 'Fixing Canada's Health Care: Lessons from Japan.' This eye-opening film will air nationwide on Sunday, August 10, 2025, at 9:00 PM ET/MT – 8PM PT. A central revelation of the film is the astonishment expressed by Japanese interviewees when informed that Canadians often endure year-long waits for common surgeries such as knee and hip operations. In stark contrast, patients in Japan can typically receive these procedures within a couple of weeks. The documentary explores two major systemic differences between the two countries that contribute to this disparity, offering valuable insights for the ongoing discussion about healthcare reform in Canada. Produced by the Canadian think tank , 'Fixing Canada's Health Care: Lessons from Japan' delves into the stark differences between the Canadian and Japanese healthcare systems, focusing on Japan, a country with virtually no health care waiting lists. The documentary was shot in May 2025 and features candid interviews with hospital officials, academics, patients, and other key figures in Japan. 'We are committed to bringing thought-provoking and impactful content to our viewers, and 'Fixing Canada's Health Care: Lessons from Japan' is precisely that,' says Tore Stautland, CEO of The News Forum. 'This documentary provides a crucial external perspective on a challenge that affects millions of Canadians, and we believe it will spark important conversations about potential solutions.' 'Our goal with this documentary is to show Canadians that there are alternative approaches to healthcare delivery that result in significantly better patient outcomes, particularly when it comes to waiting lists,' adds Colin Craig, President of . 'Japan's system offers compelling lessons, and we are grateful to The News Forum for providing a platform to share these findings with a national audience.' 'Fixing Canada's Health Care: Lessons from Japan' is a timely and essential examination of a critical issue facing Canadians. Its exclusive broadcast on The News Forum offers a unique opportunity for viewers to explore innovative ideas for improving healthcare access and efficiency. Tune in to 'Fixing Canada's Health Care: Lessons from Japan' on Sunday, August 10, 2025, at 9:00 PM ET/MT – 8PM PT, only on The News Forum. Check your local listings for channel information or visit . About The News Forum The News Forum is a national Canadian news broadcaster available through most television distributors – see local listings. TNF is a proud subscriber to the Canadian Press/AP along with other significant sources of breaking news from across Canada and around the world. About is a public policy think tank that launched in 2019. 's mission is to tell the stories of ordinary Canadians and demonstrate how public policy decisions harm or help their prosperity, freedom and lives. Media Contact Danielle Klammer CMO, The News Forum 604.626.6993 Additional Information: Website: Forum Daily News Website: Twitter: Facebook: Instagram: YouTube: TikTok:
